top of page
gradientForSurfBreak.png

Item List

EIN News
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma multiforme (GBM).

Recent Posts

Wavemaker 360 News

Carlsmed.png

Episode 108: Jay Goss, General Partner at Wavemaker Three-Sixty Health ...

MedTech Money

Portfolio Company

Carlsmed.png

Strados Labs forms collaboration with Boehringer Ingelheim for its Idiopathic Pu ...

Cision PR Newsire

Portfolio Company

Carlsmed.png

Caduceus Capital Partners, Wavemaker Three-Sixty Health Co-Lead Series A Investm ...

Businesswire

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page